Clinical trials: Stage III Non-Small Cell Lung Cancer AJCC v7
Stage III Non-small Cell Lung Cancer, Individualized Radiation Dose Escalation
Individualized Dose Prescription in Advanced Stage Lung Cancer Patients Using Modern (Chemo)Radiotherapy
The aim of this present study is to test the feasibility and toxicity of individualized hypofractionated radiotherapy, and to report outcome data.
- Trial name
- IDEAL-VMAT (NCT01577212)
- Testing
- Individualized dose escalation
- Where
- Netherlands
- Volunteers
- 6 people
- Sponsor
- Radboud University Medical Center
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer
Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Conditions
- Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer
- Trial name
- NCT00005838
- Testing
- shark cartilage extract AE-941, cisplatin, vinorelbine tartrate
- Where
- United States
- Volunteers
- 756 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small-Cell Lung Carcinoma
Concurrent Helical Tomotherapy With Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
This non-randomized Phase I/II study is designed to determine the maximum tolerated dose (MTD) of thoracic radiotherapy and concurrent chemotherapy with cisplatin and docetaxel in patients with LA-NSCLC.
- Trial name
- NCT00379717
- Testing
- Cisplatinum, Docetaxel, Tomotherapy
- Where
- Belgium
- Volunteers
- 30 people
- Sponsor
- Universitair Ziekenhuis Brussel
Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery.
- Conditions
- Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8
- Trial name
- NCT02194738
- Testing
- Biospecimen Collection, Carboplatin, Cisplatin
- Where
- 1,660 sites in United States, Guam and 1 more
- Volunteers
- 7,458 people
- Sponsor
- National Cancer Institute (NCI)
Non Small-cell Lung Cancer
Chemotherapy/Radiotherapy Versus Concomitant Chemotherapy Followed by Radiotherapy in Stage IIIB Non-small Cell Lung Cancer
Randomized study in 2 arms, without any masking in patients with non small cell lung cancer, histologically or cytologically confirmed, not liable to surgery, stage IIIB or IIIA, according to the TNM classification of the…
- Trial name
- GECP0008 (NCT01652820)
- Testing
- Docetaxel 20mg/m2/week + carboplatin AUC 2/weekly - concomitant chemoradiation 2Gy/day, Docetaxel 40mg<7m2 d1,8, 21, 28+ gemcitabine 1200mg/m2 d1,8, 21, 28 + concomitant docetaxel 20mg/m2/w+carboplatin AUC 2/w+ concomitant RDT 2Gy/d
- Volunteers
- 140 people
- Sponsor
- Spanish Lung Cancer Group
Lung Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004093
- Testing
- carboplatin, Gemcitabine, paclitaxel
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Northwestern University
Small Cell Lung Cancer, Limited Stage, Stage III Non-small Cell Lung Cancer
Image-Guided Functional Lung Avoidance Thoracic Radiotherapy for Lung Cancer: A Single-Blind Randomized Trial
Thoracic radiotherapy (TRT) is a standard curative treatment for locally advanced, unresectable non-small cell lung cancer (NSCLC) and limited stage small cell lung cancer (SCLC).
- Trial name
- NCT03077854
- Testing
- Functional Lung Avoidance Thoracic Radiotherapy, Standard Thoracic Radiotherapy
- Where
- Taiwan
- Volunteers
- 64 people
- Sponsor
- National Taiwan University Hospital
Non-Small Cell Lung Cancer
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with eligible biomarker status as determined by Version 8 of the American Joint Committee…
- Trial name
- HORIZON 1 (NCT05170204)
- Testing
- Alectinib, Entrectinib, Durvalumab
- Where
- 45 sites in United States, Australia and 17 more
- Volunteers
- 68 people
- Sponsor
- Hoffmann-La Roche
Bronchial Cancer
Efficacy and Safety Study of DURVALUMAB Maintenance in Patients With Stage III Non-Small Cell Lung Cancer
The aim of this study is to evaluate the real-life efficacy of durvalumab treatment in consolidation after radio-chemotherapy.
- Trial name
- DURVABREIZH (NCT06564870)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Brest
Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer
Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
Randomized phase III trial to compare the effectiveness of combination chemotherapy plus radiation therapy with or without gefitinib in treating unresectable stage III non-small cell lung cancer.
- Conditions
- Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer
- Trial name
- NCT00020709
- Testing
- cisplatin, docetaxel, etoposide
- Where
- United States
- Volunteers
- 840 people
- Sponsor
- National Cancer Institute (NCI)
Unresectable Stage III Non-small Cell Lung Cancer, Tislelizumab
Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC
The goal of this phase 2 trial is to evaluate the efficacy and safety of tislelizumab combined with intravenous chemotherapy and bronchial artery chemoembolization (BACE) as conversion therapy for patients with initially…
- Conditions
- Unresectable Stage III Non-small Cell Lung Cancer, Tislelizumab, Chemotherapy, Chemoembolization, Therapeutic
- Trial name
- BEACON-Lung (NCT07561983)
- Testing
- Tislelizumab, Intravenous Chemotherapy, Bronchial Artery Chemoembolization (BACE)
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute